Kinase inhibitors and drug delivery based on nanoparticles in cancer treatment with the help of artificial intelligence

Kinase inhibitors and drug delivery based on nanoparticles in cancer treatment with the help of artificial intelligence

دکتر بهزاد زنجانی نژاد1 نفیسه مرئی2 نیوشا کریمی طاری3 راضیه الیکایی4

1) دکتری مهندسی انرژی
2) ارشد شیمی دارویی
3) کارشناسی شیمی کاربردی
4) کارشناسی شیمی کاربردی

IOI Code : AZEK-AADAAH
Publication : 4th International Conference on New Research & Achievements in Science, Engineering & Technologies(setbconf.com)
Abstract :
    Cancer is a great threat to global public health. It is one of the main causes of significant morbidity and global deaths per year in 2022, approximately 1,918,030 cancer cases and 609,360 cancer related deaths were reported, and 26 million new cancer cases are projected to occur by 2030. Monoclonal antibodies possess a diverse set of clinically relevant mechanisms of action. In addition, antibodies can directly target tumor cells while simultaneously promoting the induction of longlasting anti-tumor immune responses. Antibodies are unique in their ability to both directly kill tumor cells while simultaneously engage the host immune system to develop long-lasting effector responses against the tumor. Targeted mAbs against antigens either unique to or overexpressed by tumor cells can cause tumor cell death by a variety mechanism.

Keywords : cancer protein kinase phospholipid artificial intelligence global health